<DOC>
	<DOC>NCT00476554</DOC>
	<brief_summary>This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies.</brief_summary>
	<brief_title>A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<criteria>Adult patients with advanced CTCL Have had at least 2 systemic therapies Must have evaluable disease Eastern Cooperative Oncology Group performance status 02 Adequate bone marrow, hepatic and renal function At least 3 weeks from prior therapies Not receiving topical steroids or have been on a stable dose of topical steroids for at least 2 weeks Able to swallow capsules At least 3 weeks from major surgery Agree to practice effective contraception Able to understand and willing to sign the informed consent form Receiving systemic steroids Receiving topical or systemic retinoids or vitamin A Receiving radiotherapy, biological therapy,or any other investigational agents Uncontrolled intercurrent illness Pregnant or lactating women Known to be HIVpositive Active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CTCL</keyword>
</DOC>